| Host: |
Rabbit |
| Applications: |
WB/ELISA |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH 7.3. |
| Purification: |
Affinity purification |
| Concentration: |
Lot specific |
| Dilution Range: |
WB:1:500-1:2000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Gene Symbol: |
EIF4A1 |
| Gene ID: |
1973 |
| Uniprot ID: |
IF4A1_HUMAN |
| Specificity: |
A synthetic peptide of human Methyl-eIF4A1-H132, 3-methyl (tau-methyl). |
| Function | ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. As a result, promotes cell proliferation and growth. |
| Protein Name | Eukaryotic Initiation Factor 4a-IEif-4a-IEif4a-IAtp-Dependent Rna Helicase Eif4a-1 |
| Database Links | Reactome: R-HSA-1169408Reactome: R-HSA-156827Reactome: R-HSA-429947Reactome: R-HSA-72649Reactome: R-HSA-72662Reactome: R-HSA-72702Reactome: R-HSA-72706Reactome: R-HSA-9820841Reactome: R-HSA-9820865 |
| Cellular Localisation | CytoplasmPerinuclear RegionCell MembraneStress GranuleColocalizes With Pkp1 In Stress Granules Following Arsenate Or Hydrogen Peroxide Treatment |
| Alternative Antibody Names | Anti-Eukaryotic Initiation Factor 4a-I antibodyAnti-Eif-4a-I antibodyAnti-Eif4a-I antibodyAnti-Atp-Dependent Rna Helicase Eif4a-1 antibodyAnti-EIF4A1 antibodyAnti-DDX2A antibodyAnti-EIF4A antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
